Funded Biotechnology Startups in Finland
The 24 most recently funded biotechnology companies in Finland span subsectors from drug delivery (Nanoform, Helsinki) and gene therapy (Valo Therapeutics,…
The 24 most recently funded biotechnology companies in Finland span subsectors from drug delivery (Nanoform, Helsinki) and gene therapy (Valo Therapeutics, FinVector) to protein fermentation (Enifer, Onego Bio) and textile biotech (Infinited Fiber Company). Southern Finland dominates the geography, with Helsinki and Espoo together accounting for 14 of the 24 entries. Kuopio in Eastern Finland appears twice, hosting FinVector ($48M, June 2023) and Aurealis Therapeutics ($9M, November 2024).
Round sizes vary considerably: FinVector's $48M and Infinited Fiber Company's $30M sit at the upper end, while five companies raised at Seed stage and Solu closed a $1M Pre-Seed in June 2023. Two companies — Enifer and Solar Foods — have reached Series B. Funding activity has continued into 2025, with Valo Therapeutics ($21M, March), Herantis Pharma ($5M, February), StemSight ($2M, February), and Nanoform ($6M, June) all closing rounds within the past year.
Most recent rounds
24 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these 24 companies?
FinVector (Kuopio) leads at $48M in June 2023, followed by Infinited Fiber Company (Espoo) at $30M in March 2024 and Onego Bio (Helsinki) at $29M in April 2024. Valo Therapeutics rounds out the top four at $21M, closed in March 2025.
Which cities account for the most companies in this list?
Helsinki appears in 10 of the 24 entries, and Espoo in 4, making Southern Finland the dominant cluster with 14 companies. Tampere and Turku each host 3 companies, while Kuopio (FinVector, Aurealis Therapeutics), Seinäjoki, and Oulu each contribute one or two.
How many of these companies have reached Series B or later?
Two companies in this set have closed disclosed Series B rounds: Enifer (Espoo, $16M, May 2024) and Solar Foods (Helsinki, $9M, April 2024). Onego Bio and Algorithmiq each raised Series A rounds at $29M and $15M respectively, both in 2023–2024.
How active has Finnish biotech funding been in 2025 so far?
Four rounds appear in the first half of 2025: Valo Therapeutics ($21M, March), Herantis Pharma ($5M, February), StemSight ($2M, February), and Nanoform ($6M, June). Three of the four are classified as Series Unknown and one (StemSight) as Seed.
Does Finnish biotech funding extend beyond pharma and therapeutics?
Yes — the list includes protein fermentation (Solar Foods, Enifer, Onego Bio), textile fiber recycling (Infinited Fiber Company, Espoo, $30M), marine biotech (Origin by Ocean, Espoo), and diagnostics and lab services (Resistomap, Measurlabs, NADMED), alongside cell therapy and neurology-focused companies.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.